Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986657 · ClinicalTrials.gov registry record · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
A NA study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 325
- Enrollment target
- 1
- Study location
NCT04986657: Recruiting NA study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Washington University School of Medicine.
NCT04986657 is a NA study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Washington University School of Medicine. The registered enrollment target is 325 participants, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (183% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04986657, a NA study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Washington University School of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 325 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for patients with the diagnoses of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
Primary Outcome
* As compared to conventional cytogenetics in a real-time clinical setting * The total number of recurrent structural variants will be measured in each sample by ChromoSeq and metaphase cytogenetics yielding a pair of measurements. Each measurement will also be dichotomized into the presence or absence of at least one recurrent structural variant. The hypothesis of no difference in the number of variants detected by each method will be analyzed by a paired-sample t-test. However, if it is determ
Conditions Studied
Interventions
- DEVICE ChromoSeq
Study Locations (1)
Missouri
- Washington University School of Medicine - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT04986657 shows while recruiting
NCT04986657 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, above the 115-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (183% higher).
The record links to 3 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which ChromoSeq is the first listed.
NCT04986657 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT04986657 about?
NCT04986657 is a clinical study titled "Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS". This is a single institution, prospective study of the whole genome sequencing assay, ChromoSeq. Using prospectively collected patient data, coupled with physician surveys, the investigators seek to determine the feasibility of implementing ChromoSeq in addition to standard genomic testing, for pati...
What is the current status of trial NCT04986657?
This trial is currently recruiting. It is a NA study. The enrollment target is 325 participants. The study started on 2021-09-17. Estimated completion is 2027-12-31.
What conditions does trial NCT04986657 study?
This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Whole Genome Sequencing.
What interventions are being tested in trial NCT04986657?
The interventions under investigation include: ChromoSeq (DEVICE).
Who is sponsoring clinical trial NCT04986657?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04986657 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Myeloid Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04986657's enrollment target sits among peer trials
325 19th of 306 higher than 288 of 306 other Acute Myeloid Leukemia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Myeloid Leukemia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ONC-LEUK-2406: The Impact of Systematic Financial Navigation in Acute Myeloid Leukemia
RECRUITING · NA
-
A Telehealth Advance Care Planning Intervention
RECRUITING · NA
-
Massage Impact on Sleep in Pediatric Oncology
RECRUITING · NA
-
Home Blood Transfusions
RECRUITING · NA
-
Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
RECRUITING · NA
-
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT06038318 · 325 participants · NA
Promoting Resilience in Early Survivorship Among Adolescents and Young Adults With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI